IP Library Patent Application 11667615
Patent Application
App. No. 11/667,615

Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/667,615
Abstract

A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Claims (13)

1 . A method of treating diabetes, comprising administering to an individual having diabetes a composition comprising a first component selected from a curcuminoid and a second component selected from an alpha acid and a beta acid.

2 . The method of claim 1 , wherein said curcuminoid is selected from curcumin, demethoxycurcumin, and bisdemethoxycurcumin.

3 . The method of claim 1 , wherein the alpha acids are selected from the group consisting of humulone, cohumulone, isohumulone, isoprehumulone, hulupone, adhumulone, xanthohumol A and xanthohumol B.

4 . The method of claim 1 , wherein the beta acids are selected from the group consisting of lupulone, colupulone, adlupulone, tetrahydroisohumulone, hexahydrocolupulone, and dihydro-isohumulone.

5 . The method of claim 1 , wherein said composition is formulated in a pharmaceutically acceptable carrier.

6 . The method of claim 1 , wherein said composition further comprises one or more members selected from the group consisting of antioxidants, vitamins and minerals.

7 . The method of claim 1 , wherein said composition further comprises one or more members selected from the group consisting of proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.

8 . The method of claim 1 , wherein said first or second component is conjugated with monosaccharides, disaccharides, amino acids, sulfates, succinates, acetates or glutathione.

9 . A method of treating diabetes, comprising administering to an individual having diabetes a composition comprising a hops CO 2 extract.

10 . The method of claim 9 , wherein the alpha acids are selected from the group consisting of humulone, cohumulone, isohumulone, isoprehumulone, hulupone, adhumulone, xanthohumol A and xanthohumol B.

11 . The method of claim 9 , wherein the beta acids are selected from the group consisting of lupulone, colupulone, adlupulone, tetrahydroisohumulone, hexahydrocolupulone, and dihydro-isohumulone.

12 . The method of claim 9 , wherein the essential oils are selected from the group consisting of myrcene, humulene, beta-caryophyleen, undecane-2-on, and 2-methyl-but-3-en-ol.

13 . The method of claim 9 , wherein said composition is formulated in a pharmaceutically acceptable carrier.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2007
From: BABISH, JOHN G.; HOWELL, TERRENCE M.; PACIORETTY, LINDA M.
To: METAPROTEOMICS, LLC
Reel/Frame 020169/0781 →